Trial drug can significantly block early stages of COVID-19 in engineered human tissues
- Details
- Category: Research
An international team led by University of British Columbia researcher Dr. Josef Penninger has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts. The findings, published in Cell, hold promise as a treatment capable of stopping early infection of the novel coronavirus.
Possible coronavirus drug identified by Australian scientists
- Details
- Category: Research
A collaborative study led by Monash University's Biomedicine Discovery Institute (BDI) in Melbourne, Australia, with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), has shown that an anti-parasitic drug already available around the world kills the virus within 48 hours.
Clues to COVID-19 coronavirus's vulnerability emerge from an antibody against SARS
- Details
- Category: Research
An antibody recovered from a survivor of the SARS epidemic in the early 2000s has revealed a potential vulnerability of the new coronavirus at the root of COVID-19, according to a study from scientists at Scripps Research.
The study, published today in Science, is the first to map a human antibody's interaction with the new coronavirus at near-atomic-scale resolution.
Experimental AI tool predicts which COVID-19 patients develop respiratory disease
- Details
- Category: Research
An artificial intelligence tool accurately predicted which patients newly infected with the COVID-19 virus would go on to develop severe respiratory disease, a new study found. The work was led by NYU Grossman School of Medicine and the Courant Institute of Mathematical Sciences at New York University, in partnership with Wenzhou Central Hospital and Cangnan People's Hospital, both in Wenzhou, China.
Nafamostat is expected to prevent the transmission of new coronavirus infection (COVID-19)
- Details
- Category: Research
Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19). The University of Tokyo announced these new findings on March 18, 2020.
Singapore modelling study estimates impact of physical distancing on reducing spread of COVID-19
- Details
- Category: Research
A new modelling study conducted in a simulated Singapore setting has estimated that a combined approach of physical distancing [2] interventions, comprising quarantine (for infected individuals and their families), school closure, and workplace distancing, is most effective at reducing the number of SARS-CoV-2 cases compared with other intervention scenarios included in the study.
CAR macrophages go beyond T cells to fight solid tumors
- Details
- Category: Research
Chimeric antigen receptor (CAR) T cell therapy has been a game-changer for blood cancers but has faced challenges in targeting solid tumors. Now researchers from the Perelman School of Medicine at the University of Pennsylvania may have an alternative to T cell therapy that can overcome those challenges.
More Pharma News ...
- Vivli to launch a portal for sharing data from COVID-19 trials
- Understanding how COVID-19 affects children vital to slowing pandemic
- The COVID-19 coronavirus epidemic has a natural origin
- COVID-19: The immune system can fight back
- New kind of CRISPR technology to target RNA, including RNA viruses like coronavirus
- A world premiere from Erasmus MC and Utrecht University: they found an antibody against COVID-19
- Statins starve cancer cells to death